Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart Failure

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Clinical consequences of angiotensin-converting enzyme inhibitor withdrawl in chronic heart failure: A double-blind, placebo-controlled study of quinapril1993 · 95 citations
2. 2Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus2016 · 141 citations
3. 3The Impact of Discontinuation of Sacubitril-Valsartan and Shifting to Angiotensin-Converting Enzyme inhibitor or Angiotensin Receptor Blocker in Patients with Heart Failure with Reduced Ejection Fraction2020 · 5 citations
4. 4Acute Pharmacodynamic Effects of Empagliflozin With and Without Diuretic Agents in Patients With Type 2 Diabetes Mellitus2016 · 57 citations
5. 5Functional Role of Glucose Metabolism, Osmotic Stress, and Sodium-Glucose Cotransporter Isoform-Mediated Transport on Na+/H+ Exchanger Isoform 3 Activity in the Renal Proximal Tubule2014 · 185 citations